

**From:** [Heidi Liivamagi](#)  
**To:** [AGO - Public Records Requests](#)  
**Cc:** [Alyssa Brown](#)  
**Subject:** Open Records Law Request - Cencora, Inc., The Lash Group, LLC, and Related Entities  
**Date:** Friday, December 13, 2024 11:12:06 PM  
**Attachments:** [image001.png](#)  
[Cencora - FOIA Request - VT.pdf](#)

---

Some people who received this message don't often get email from hliivamagi@ahdootwolfson.com. [Learn why this is important](#)

**EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.**

Dear Sir/Madam,

Attached please find an Open Records Law Request regarding Cencora, Inc., The Lash Group, LLC, and Related Entities. A had copy of the same request has been sent via Certified Mail.

Sincerely,

Heidi Liivamagi  
Paralegal



201 King of Prussia Road | Suite 650

Radnor, Pennsylvania 19087

Tel: [\(310\) 474-9111](tel:(310)474-9111) x 25

Direct: (626) 678-1341

Fax: (310) 474-8585

[hliivamagi@ahdootwolfson.com](mailto:hliivamagi@ahdootwolfson.com)



December 12, 2024

**VIA CERTIFIED U.S. MAIL AND EMAIL**

Vermont Attorney General's Office  
Public Records Act Request  
109 State Street  
Montpelier, VT 05609-1001  
ago.publicrecordsrequests@vermont.gov

**Re: Public Records Law Request  
Cencora, Inc., The Lash Group, LLC, and Related Entities**

Dear Sir or Madam:

Pursuant to the Vermont Public Records Law (§315 *et seq.*), this letter serves as a request for all documents relating to any investigation, review, or correspondence regarding the data breach that was disclosed by Cencora, Inc. ("Cencora") to the Securities Exchange Commission in a public filing on or about February 27, 2024, and to some affected consumers on or about May 17, 2024 (the "Data Breach") (*see* Exh. A). The Data Breach also affected/included the following related entities: (1) The Lash Group, LLC, a subsidiary of Cencora; (2) Bristol-Myers Squibb Company; (3) Bristol-Myers Squibb Patient Assistance Foundation, Inc.; (4) Glaxosmithkline LLC; (5) Glaxosmithkline Patient Access Programs Foundation; (6) Sumitomo Pharma America, Inc.; (7) Regeneron Pharmaceuticals, Inc.; (8) Abbott; (9) AbbVie, Inc.; (10) Acadia Pharmaceuticals, Inc.; (11) Acrotech Biopharma, Inc.; (12) Amgen, Inc.; (13) Bausch Health Companies, Inc.; (14) Bayer Corporation; (15) CareDx, Inc.; (16) Dendreon Pharmaceuticals LLC; (17) Endo Pharmaceuticals, Inc.; (18) Genentech, Inc.; (19) Heron Therapeutics, Inc.; (20) Incyte Corporation; (21) Johnson & Johnson Services, Inc. and Johnson & Johnson Patient Assistance Foundation, Inc.; (22) Marathon Pharmaceuticals, LLC/PTC Therapeutics, Inc.; (23) Novartis Pharmaceuticals Corporation; (24) Otuska America Pharmaceutical, Inc.; (25) Pfizer, Inc.; (26) Pharming Healthcare, Inc.; (27) Rayner Surgical, Inc.; (28) Sandoz, Inc.; (29) Takeda Pharmaceuticals U.S.A., Inc.; and (30) Tolmar (collectively, the "Related Entities").

Please send a copy of all documents and communications relating to the Data Breach, including, but not limited to, any documents or communications with or pertaining to Cencora and/or its Related Entities by or with the Office of the Vermont Attorney General.

This request includes, without limitation, the following types of documents: 1) all written correspondence with Cencora and/or the Related Entities concerning the Data Breach; 2) all documents relating to Cencora's and/or the Related Entities' protection, the unauthorized access of, or disclosure of personally identifiable information during or related to the Data Breach, 3) all documents concerning

Cencora's and/or the Related Entities' post-Data Breach remedial efforts, including documents and communications with the Office of the Vermont Attorney General regarding notice of the Data Breach, 4) any other documents and communications in your possession relating to the Data Breach, and 5) any documents or information pertaining to any investigation of Cencora and/or the Lash Group related to the Data Breach. Please also provide all documents relating to any other separate data breaches or data security incidents, including investigations thereof, involving Cencora and the Lash Group since January 1, 2020.

Please send all documents responsive to this request to the following address:

Ahdoot & Wolfson, PC  
ATTN: Robert Ahdoot  
2600 W. Olive Avenue, Suite 500  
Burbank, California 91505

I am a partner at Ahdoot & Wolfson, PC, a law firm that represents Plaintiffs in the consolidated putative Class Action *Anaya, et al. v. Cencora, Inc., et al.*, No. 24-2961 (E.D. Pa.). This request is made as part of our investigation concerning the facts of the case and is not intended for a commercial use. Ahdoot & Wolfson, PC is willing to pay fees for this request up to a maximum of \$500. If you estimate that the fees will exceed this limit, please contact me at (310) 474-9111.

Thank you for your consideration.

Sincerely,



Robert Ahdoot

# **Exhibit A**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 21, 2024

**Cencora, Inc.**

(Exact name of registrant as specified in its charter)

Commission File Number: **1-6671**

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**1 West First Avenue Conshohocken PA**  
(Address of principal executive offices)

**23-3079390**  
(I.R.S. Employer  
Identification No.)

**19428-1800**  
(Zip Code)

**(610) 727-7000**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report.)

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common stock	COR	New York Stock Exchange (NYSE)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 1.05 Material Cybersecurity Incidents.**

On February 21, 2024, Cencora, Inc. (the “Company”), learned that data from its information systems had been exfiltrated, some of which may contain personal information. Upon initial detection of the unauthorized activity, the Company immediately took containment steps and commenced an investigation with the assistance of law enforcement, cybersecurity experts and external counsel.

As of the date of this filing, the incident has not had a material impact on the Company’s operations, and its information systems continue to be operational. The Company has not yet determined whether the incident is reasonably likely to materially impact the Company’s financial condition or results of operations.

***Forward-Looking Statements***

Certain of the statements contained in this Current Report on Form 8-K are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”). Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially from those indicated is included in the “Risk Factors” and “Management’s Discussion and Analysis” sections in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 and elsewhere in that report and (ii) other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cencora, Inc.

February 27, 2024

By: /s/ James F. Cleary

Name: James F. Cleary

Title: Executive Vice President and Chief Financial Officer

---